Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Bentracimab in Chinese Healthy Volunteers
NCT05162131Phase 1Terminated
- Sponsor
- SFJ Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bentracimab in hemorrhage (7 cohorts), sponsored by SFJ Pharmaceuticals. Primary endpoints: Incidence and severity of Adverse Events at 60 days, Incidence of Clinical Laboratory Abnormalities at 30 days and 3 more. Started Dec 2021; status: terminated.
02
Drugs
bentracimab
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT05162131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162131.